- Home
- KPRX vs CANF Comparison
KPRX vs CANF Comparison
Compare KPRX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- CANF
- Stock Information
- Founded
- KPRX 1998
- CANF 1994
- Country
- KPRX United States
- CANF Israel
- Employees
- KPRX N/A
- CANF N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- CANF Health Care
- Exchange
- KPRX Nasdaq
- CANF Nasdaq
- Market Cap
- KPRX 9.2M
- CANF 9.6M
- IPO Year
- KPRX N/A
- CANF N/A
- Fundamental
- Price
- KPRX $2.65
- CANF $0.65
- Analyst Decision
- KPRX Strong Buy
- CANF Strong Buy
- Analyst Count
- KPRX 1
- CANF 2
- Target Price
- KPRX $10.00
- CANF $14.50
- AVG Volume (30 Days)
- KPRX 32.4K
- CANF 165.4K
- Earning Date
- KPRX 11-07-2025
- CANF 08-26-2025
- Dividend Yield
- KPRX N/A
- CANF N/A
- EPS Growth
- KPRX N/A
- CANF N/A
- EPS
- KPRX N/A
- CANF N/A
- Revenue
- KPRX N/A
- CANF $560,000.00
- Revenue This Year
- KPRX N/A
- CANF $461.72
- Revenue Next Year
- KPRX N/A
- CANF N/A
- P/E Ratio
- KPRX N/A
- CANF N/A
- Revenue Growth
- KPRX N/A
- CANF N/A
- 52 Week Low
- KPRX $2.25
- CANF $0.63
- 52 Week High
- KPRX $4.18
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- KPRX 46.53
- CANF 35.66
- Support Level
- KPRX $2.60
- CANF $0.64
- Resistance Level
- KPRX $2.80
- CANF $0.68
- Average True Range (ATR)
- KPRX 0.11
- CANF 0.02
- MACD
- KPRX -0.01
- CANF 0.01
- Stochastic Oscillator
- KPRX 21.21
- CANF 42.50
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).